More on INCY
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $103.66 |
|
|||
| Open | $103.66 | ||||
| 52 Wk High | $118.49 | ||||
| 52 Wk Low | $55.00 | ||||
| Day High | $103.66 | ||||
| Day Low | $103.66 | ||||
| P/E | N/A | ||||
| EPS | $-0.56 | ||||
| Volume | 578 | ||||
- Incyte (INCY) PT Raised to $105 at Truist Securities
- Incyte settles CMS lawsuit over Opzelura Medicaid rebate rules
- Form 8-K INCYTE CORP For: Jun 22
- BMO Capital Upgrades Incyte (INCY) to Market Perform
- Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- BMO Capital on Incyte (INCY): ''989 Updates Provide More Context to ET/MF Opportunity'
- Stifel Reiterates Buy Rating on Incyte (INCY)
- Mirum and Incyte report positive phase 2 results for FOP treatment
- Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
- NASDAQ: INCY shows 25% reduction in disease progression risk in lymphoma study
Entities mentioned with INCY
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
